TWI574690B - 立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物 - Google Patents

立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物 Download PDF

Info

Publication number
TWI574690B
TWI574690B TW101142278A TW101142278A TWI574690B TW I574690 B TWI574690 B TW I574690B TW 101142278 A TW101142278 A TW 101142278A TW 101142278 A TW101142278 A TW 101142278A TW I574690 B TWI574690 B TW I574690B
Authority
TW
Taiwan
Prior art keywords
group
nilotinib
dosage form
methyl
solid dosage
Prior art date
Application number
TW101142278A
Other languages
English (en)
Chinese (zh)
Other versions
TW201325594A (zh
Inventor
約普克兒 布哈爾德瓦
曼吉斯 撒搭斯夫 薄達維卡爾
安 蕾茲 寇福特
李萍
李尚鋒
艾雷克斯 馬克羅夫
Original Assignee
諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 諾華公司 filed Critical 諾華公司
Publication of TW201325594A publication Critical patent/TW201325594A/zh
Application granted granted Critical
Publication of TWI574690B publication Critical patent/TWI574690B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW101142278A 2011-11-14 2012-11-13 立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物 TWI574690B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14

Publications (2)

Publication Number Publication Date
TW201325594A TW201325594A (zh) 2013-07-01
TWI574690B true TWI574690B (zh) 2017-03-21

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101142278A TWI574690B (zh) 2011-11-14 2012-11-13 立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物

Country Status (23)

Country Link
EP (1) EP2779995A1 (https=)
JP (1) JP6275645B2 (https=)
KR (1) KR20140093230A (https=)
CN (1) CN103930094A (https=)
AR (1) AR088844A1 (https=)
BR (1) BR112014011518A2 (https=)
CA (1) CA2855503A1 (https=)
CL (1) CL2014001247A1 (https=)
CO (1) CO6960546A2 (https=)
EA (1) EA201490960A1 (https=)
GT (1) GT201400094A (https=)
HK (1) HK1197025A1 (https=)
IL (1) IL232480A0 (https=)
IN (1) IN2014DN03416A (https=)
MA (1) MA35636B1 (https=)
MX (1) MX2014005874A (https=)
PE (1) PE20141337A1 (https=)
PH (1) PH12014501062B1 (https=)
SG (2) SG10201707768RA (https=)
TN (1) TN2014000177A1 (https=)
TW (1) TWI574690B (https=)
WO (1) WO2013074432A1 (https=)
ZA (1) ZA201402756B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP7489849B2 (ja) * 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
JP7776274B2 (ja) * 2021-07-19 2025-11-26 日本化薬株式会社 ニロチニブ錠剤およびその製造方法
JP7776275B2 (ja) * 2021-07-26 2025-11-26 日本化薬株式会社 ニロチニブ錠剤およびその製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2012164578A1 (en) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions and methods for preparing immediate release formulations of nilotinib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kleinebudde Peter;"Roll compaction/dry granulation:pharmaceutical applications";European Journal of Pharmaceutics and Biopharmaceutics,2004,vol.58,pages 317~326. *

Also Published As

Publication number Publication date
HK1197025A1 (en) 2015-01-02
MX2014005874A (es) 2014-06-23
TN2014000177A1 (en) 2015-09-30
MA35636B1 (fr) 2014-11-01
KR20140093230A (ko) 2014-07-25
JP6275645B2 (ja) 2018-02-07
AR088844A1 (es) 2014-07-10
AU2012339829B2 (en) 2016-05-12
AU2012339829A1 (en) 2014-05-29
CL2014001247A1 (es) 2014-10-17
EP2779995A1 (en) 2014-09-24
PE20141337A1 (es) 2014-10-16
SG10201707768RA (en) 2017-10-30
JP2014533283A (ja) 2014-12-11
TW201325594A (zh) 2013-07-01
SG11201401476TA (en) 2014-10-30
WO2013074432A1 (en) 2013-05-23
CN103930094A (zh) 2014-07-16
ZA201402756B (en) 2015-04-29
IL232480A0 (en) 2014-06-30
NZ623844A (en) 2016-09-30
CA2855503A1 (en) 2013-05-23
BR112014011518A2 (pt) 2017-05-16
PH12014501062A1 (en) 2014-06-23
IN2014DN03416A (https=) 2015-06-26
GT201400094A (es) 2017-09-28
CO6960546A2 (es) 2014-05-30
EA201490960A1 (ru) 2014-08-29
PH12014501062B1 (en) 2018-04-20

Similar Documents

Publication Publication Date Title
US20150273070A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(triflouoromethyl)phenyl] benzamide solubilized using organic acids
US8501760B2 (en) Pharmaceutical compositions comprising nilotinib or its salt
AU2007297333B2 (en) Solid dosage form of olmesartan medoxomil and amlodipine
TWI574690B (zh) 立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物
EP2540318A1 (en) Sustained-release solid preparation for oral use
US9301957B2 (en) Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
US20140010876A1 (en) Pharmaceutical administration forms comprising 5-chloro-n-(methyl)-2-thiophenecarboxamide
WO2013172297A1 (ja) ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有製剤
AU2012339829B8 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
CN107205984B (zh) 吡咯甲酰胺的固体组合物
NZ623844B2 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
JP2020075923A (ja) エルロチニブを有効成分とする医薬錠剤
AU2012271746A1 (en) Modified release of 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl) benzamide solubilized using organic acids
HK1225281B (zh) 包含1-[6-(吗啉-4-基)嘧啶-4-基]-4-(1h-1，2，3-三唑-1-基)-1h-吡唑-5-醇钠的药物剂型

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees